Seeking Alpha
09 Sept 2026, 16:13 UTC · 10w ago
Phathom Pharmaceuticals: Specialist Economics Strengthens The Bull Case
Impact · against what's priced in
Phathom's strong Q2 growth and 2026 revenue guidance of $310–$325M signal a clear path to profitability and scalability. While revenue-interest financing remains a headwind, the combination of 88% revenue growth and an 80% gross margin provides a bullish outlook for VOQUEZNA's commercial adoption.
- PHAT+0.60
No priced-in read yet
- In context
Rapid 88% growth in Q2 revenue to $74.3M and high forecast gross margins of 80% demonstrate significant operating leverage and commercial validation for VOQUEZNA.
Read from the article alone





